Sign in
TerminatedPhase 1

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Key facts

Who runs it
Alfasigma S.p.A.
Where
France, Germany, Poland, Spain, and United Kingdom10 sites in 5 countriesChoose a country to see its sites
Status
Terminated
Phase
Phase 1
People taking part
9 people enrolled
Started
13 May 2024
Ended
17 Jun 2026
Type of study
Interventional, 3 groups
Treatments tested
  • Filgotinib
Record updated
15 July 2026
Why it stopped
The sponsor decided to stop recruitment and to early terminate the trial with 9 enrolled patients.

Who can take part

Age
8 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg
  • Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy; Rheumatoid factor (RF)-positive polyarthritis; RF-negative polyarthritis; Oligoarthritis; Psoriatic arthritis; Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening; Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment
  • Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis
  • Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test

Who cannot take part

  • Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria); Note: Other protocol defined Inclusion/ Exclusion criteria may apply
  • Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis)
  • Active infection that is clinically significant, as per judgment of the investigator
  • Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement)
  • Participant with persistent oligoarthritis
  • Participant with undifferentiated arthritis

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).

The 3 groups in the trial

  • Filgotinib Dose ATreatment being tested

    Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\<25 kg

    Treatment: Filgotinib

  • Filgotinib Dose BTreatment being tested

    Dose B of filgotinib tablet for participants with BW ≥25-\<60 kg

    Treatment: Filgotinib

  • Filgotinib Dose CTreatment being tested

    Dose C of filgotinib tablet for participants with BW ≥60 kg

    Treatment: Filgotinib

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis
Record updated
15 July 2026